{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:39:06Z","timestamp":1648985946155},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s11936-017-0537-3","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T04:49:53Z","timestamp":1493182193000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should Ablation Be First-Line Therapy for Patients with Paroxysmal AF?"],"prefix":"10.1007","volume":"19","author":[{"given":"Sergio","family":"Conti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"issue":"2","key":"537_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","volume":"37","author":"SS Chugh","year":"2001","unstructured":"Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37(2):371\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"537_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/circulationaha.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837\u201347. doi:\n10.1161\/circulationaha.113.005119\n\n.","journal-title":"Circulation"},{"issue":"18","key":"537_CR3","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370\u20135.","journal-title":"JAMA"},{"issue":"2","key":"537_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/circulationaha.105.595140","volume":"114","author":"Y Miyasaka","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119\u201325. doi:\n10.1161\/circulationaha.105.595140\n\n.","journal-title":"Circulation"},{"issue":"11","key":"537_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","volume":"271","author":"EJ Benjamin","year":"1994","unstructured":"Benjamin EJ, Levy D, Vaziri SM, D\u2019Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840\u20134.","journal-title":"JAMA"},{"issue":"10","key":"537_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946\u201352.","journal-title":"Circulation"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archinte.158.3.229","volume":"158","author":"PA Wolf","year":"1998","unstructured":"Wolf PA, Mitchell JB, Baker CS, Kannel WB, D\u2019Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229\u201334.","journal-title":"Arch Intern Med"},{"issue":"23","key":"537_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/nejmoa021328","volume":"347","author":"DG Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825\u201333. doi:\n10.1056\/nejmoa021328\n\n.","journal-title":"N Engl J Med"},{"issue":"2","key":"537_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jacc.2003.08.037","volume":"43","author":"VE Hagens","year":"2004","unstructured":"Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"537_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","volume":"41","author":"J Carlsson","year":"2003","unstructured":"Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"537_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/nejm200003303421302","volume":"342","author":"D Roy","year":"2000","unstructured":"Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913\u201320. doi:\n10.1056\/nejm200003303421302\n\n.","journal-title":"N Engl J Med"},{"issue":"6","key":"537_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJM198908103210629","volume":"321","author":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","year":"1989","unstructured":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. N Engl J Med. 1989;321(6):406\u201312.","journal-title":"N Engl J Med"},{"issue":"9019","key":"537_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","volume":"348","author":"AL Waldo","year":"1996","unstructured":"Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Puls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet. 1996;348(9019):7\u201312.","journal-title":"Lancet"},{"key":"537_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1161\/circep.108.824789","volume":"2","author":"H Calkins","year":"2009","unstructured":"Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2:349\u201361. doi:\n10.1161\/circep.108.824789\n\n.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","volume":"9","author":"H Calkins","year":"2012","unstructured":"Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation: developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS): endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9:632\u201396. doi:\n10.1016\/j.hrthm.2011.12.016\n\n.","journal-title":"Heart Rhythm"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/circulationaha.104.478263","volume":"112","author":"A Verma","year":"2005","unstructured":"Verma A, Natale A. Why atrial fibrillation ablation should be considered first-line therapy for some patients. Circulation. 2005;112:1214\u201331. doi:\n10.1161\/circulationaha.104.478263\n\n.","journal-title":"Circulation"},{"issue":"1","key":"537_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HCO.0b013e3282f2e27c","volume":"23","author":"A Verma","year":"2008","unstructured":"Verma A. Atrial-fibrillation ablation should be considered first-line therapy for some patients. Curr Opin Cardiol. 2008;23(1):1\u20138. doi:\n10.1097\/HCO.0b013e3282f2e27c\n\n.","journal-title":"Curr Opin Cardiol"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/circep.113.000629","volume":"7","author":"P Santangeli","year":"2014","unstructured":"Santangeli P, Di Biase L, Natale A. Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all patients with paroxysmal atrial fibrillation: pro. Circulation Arrhythm Electrophysiol. 2014;7:739\u201346. doi:\n10.1161\/circep.113.000629\n\n.","journal-title":"Circulation Arrhythm Electrophysiol"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1161\/circulationaha.108.772582","volume":"118","author":"P Ja\u00efs","year":"2008","unstructured":"Ja\u00efs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118:2498\u2013505. doi:\n10.1161\/circulationaha.108.772582\n\n.","journal-title":"Circulation"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2012.11.064","volume":"61","author":"DL Packer","year":"2013","unstructured":"Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61:1713\u201323. doi:\n10.1016\/j.jacc.2012.11.064\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.jacc.2006.08.037","volume":"48","author":"C Pappone","year":"2006","unstructured":"Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48:2340\u20137. doi:\n10.1016\/j.jacc.2006.08.037\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"537_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurheartj\/ehi583","volume":"27","author":"G Stabile","year":"2006","unstructured":"Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2006;27:216\u201321. doi:\n10.1093\/eurheartj\/ehi583\n\n.","journal-title":"Eur Heart J"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jama.2009.2029","volume":"303","author":"DJ Wilber","year":"2010","unstructured":"Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303:333\u201340. doi:\n10.1001\/jama.2009.2029\n\n.","journal-title":"JAMA"},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1001\/jama.293.21.2634","volume":"293","author":"OM Wazni","year":"2005","unstructured":"Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293:2634\u201340. doi:\n10.1001\/jama.293.21.2634\n\n.","journal-title":"JAMA"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1540-8167.2008.01303.x","volume":"20","author":"Y Khaykin","year":"2009","unstructured":"Khaykin Y, Wang X, Natale A, Wazni OM, Skanes AC, Humpries KH, et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol. 2009;20:7\u201312. doi:\n10.1111\/j.1540-8167.2008.01303.x\n\n.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"537_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1056\/nejmoa1113566","volume":"367","author":"J Cosedis Nielsen","year":"2012","unstructured":"Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. New Engl J Med. 2012;367:1587\u201395. doi:\n10.1056\/nejmoa1113566\n\n.","journal-title":"New Engl J Med"},{"key":"537_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/circep.109.848978","volume":"2","author":"Y Khaykin","year":"2009","unstructured":"Khaykin Y, Skanes AC, Champagne J, Themistoclakis S, Gula L, Rossillo A, et al. A randomized controlled trial of the efficacy and safety of electroanatomic circumferential pulmonary vein ablation supplemented by ablation of complex fractionated atrial electrograms versus potential-guided pulmonary vein antrum isolation guided by intracardiac ultrasound. Circ Arrhythm Electrophysiol. 2009;2:481\u20137. doi:\n10.1161\/circep.109.848978\n\n.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"537_CR28","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1161\/circulationaha.104.491530","volume":"111","author":"MR Karch","year":"2005","unstructured":"Karch MR, Zrenner B, Deisenhofer I, Schreieck J, Ndrepepa G, Dong J, et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation. 2005;111:2875\u201380. doi:\n10.1161\/circulationaha.104.491530\n\n.","journal-title":"Circulation"},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/europace\/euu342","volume":"17","author":"H Walfridsson","year":"2015","unstructured":"Walfridsson H, Walfridsson U, Cosedis Nielsen J, Johannessen A, Raatikainen P, Janzon M, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. Europace. 2015;17:215\u201321. doi:\n10.1093\/europace\/euu342\n\n.","journal-title":"Europace"},{"key":"537_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/europace\/euu188","volume":"17","author":"M Aronsson","year":"2015","unstructured":"Aronsson M, Walfridsson H, Janzon M, Walfridsson U, Cosedis Nielsen J, Hansen PS, et al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace. 2015;17:48\u201355. doi:\n10.1093\/europace\/euu188\n\n.","journal-title":"Europace"},{"issue":"7","key":"537_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jama.2014.467","volume":"311","author":"CA Morillo","year":"2014","unstructured":"\u2022\u2022 Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al. Radiofrequency Ablaton vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillaiton (RAAFT-2): a randomized trial. JAMA. 2014;311(7):692\u20139. doi:\n10.1001\/jama.2014.467\n\n. The RAAFT-2 multicenter randomized clinical trial demonstrated that catheter ablation was modestly superior to AADs for the prevention of atrial arrhythmias over 2\u00a0years of follow-up.","journal-title":"JAMA"},{"key":"537_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/circep.109.859116","volume":"3","author":"R Cappato","year":"2010","unstructured":"Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32\u20138. doi:\n10.1161\/circep.109.859116\n\n.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"537_CR33","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/circulationaha.113.003862","volume":"128","author":"A Deshmukh","year":"2013","unstructured":"Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation. 2013;128:2104\u201312. doi:\n10.1161\/circulationaha.113.003862\n\n.","journal-title":"Circulation"},{"key":"537_CR34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/europace\/eur065","volume":"13","author":"H Tanner","year":"2011","unstructured":"Tanner H, Makowski K, Roten L, Seiler J, Schwick N, Muller C, et al. Catheter ablation of atrial fibrillation as first-line therapy\u2014a single-centre experience. Europace. 2011;13:646\u201353. doi:\n10.1093\/europace\/eur065\n\n.","journal-title":"Europace"},{"key":"537_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/europace\/eur299","volume":"14","author":"M Namdar","year":"2012","unstructured":"Namdar M, Chierchia GB, Westra S, Sorgente A, La Meir M, Bayrak F, et al. Isolating the pulmonary veins as first-line therapy in patients with lone paroxysmal atrial fibrillation using the cryoballoon. Europace. 2012;14:197\u2013203. doi:\n10.1093\/europace\/eur299\n\n.","journal-title":"Europace"},{"issue":"23","key":"537_CR36","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/nejmoa1602014","volume":"374","author":"KH Kuck","year":"2016","unstructured":"Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235\u201345. doi:\n10.1056\/nejmoa1602014\n\n.","journal-title":"N Engl J Med"},{"key":"537_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/europace\/euu376","volume":"17","author":"A Hakalahti","year":"2015","unstructured":"\u2022 Hakalahti A, Biancari F, Cosedis Nielsen J, Raatikainen P. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace. 2015;17:370\u20138. doi:\n10.1093\/europace\/euu376\n\n. In this recent meta-analysis, catheter ablation seems to be more effective than AAD therapy as a first-line treatment for PAF. The risk of AF recurrence was significantly higher among patients treated with AADs. Young and relatively healthy patients benefitted more from early first-line catheter ablation. However, catheter ablation causes more severe side effects than AAD therapy, underlying the importance of patient selection and operator experience.","journal-title":"Europace"},{"key":"537_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1161\/circep\/114.001853","volume":"7","author":"AR Khan","year":"2014","unstructured":"Khan AR, Khan S, Sheikh MA, Khuder S, Grubb B, Moukarbel GV. Catheter ablation and antiarrhythmic drug therapy as first- or second-line therapy in the management of atrial fibrillation. Systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:853\u201360. doi:\n10.1161\/circep\/114.001853\n\n.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"537_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00392-013-0553-6","volume":"102","author":"KRJ Chun","year":"2013","unstructured":"Chun KRJ, Schmidt B, Kuck KH, Andresen D, Willems S, Spitzer SG, et al. Catheter ablation of atrial fibrillation in the young: insights from the German Ablation Registry. Clin Res Cardiol. 2013;102:459\u201368. doi:\n10.1007\/s00392-013-0553-6\n\n.","journal-title":"Clin Res Cardiol"},{"key":"537_CR40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1161\/circep.110.938860","volume":"3","author":"P Leong-Sit","year":"2010","unstructured":"Leong-Sit P, Zado E, Callans DJ, Garcia F, Lin D, Dixit S, et al. Efficacy and risk of atrial fibrillation ablation before 45\u00a0years of age. Circ Arrhythm Electrophysiol. 2010;3:452\u20137. doi:\n10.1161\/circep.110.938860\n\n.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"537_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jacc.2009.11.040","volume":"55","author":"CB deVos","year":"2010","unstructured":"deVos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725\u201331. doi:\n10.1016\/j.jacc.2009.11.040\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"537_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ahj.2004.09.053","volume":"149","author":"CR Kerr","year":"2005","unstructured":"Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489\u201396. doi:\n10.1016\/j.ahj.2004.09.053\n\n.","journal-title":"Am Heart J"},{"key":"537_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1152\/physrev.00031.2009","volume":"91","author":"U Schotten","year":"2011","unstructured":"Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265\u2013325. doi:\n10.1152\/physrev.00031.2009\n\n.","journal-title":"Physiol Rev"},{"key":"537_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0008-6363(02)00258-4","volume":"54","author":"M Allessie","year":"2002","unstructured":"Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230\u201346.","journal-title":"Cardiovasc Res"},{"key":"537_CR45","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1161\/01.CIR.92.7.1954","volume":"92","author":"MC Wijffels","year":"1995","unstructured":"Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954\u201368.","journal-title":"Circulation"},{"key":"537_CR46","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.hrthm.2013.05.013","volume":"10","author":"TJ Bunch","year":"2013","unstructured":"Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm. 2013;10:1257\u201362. doi:\n10.1016\/j.hrthm.2013.05.013\n\n.","journal-title":"Heart Rhythm"},{"key":"537_CR47","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/01.cir.0000090685.13169.07","volume":"108","author":"M Hocini","year":"2003","unstructured":"Hocini M, Sanders P, Deisenhofer I, Jais P, Hsu LF, Scavee C, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation. 2003;108:1172\u20135. doi:\n10.1161\/01.cir.0000090685.13169.07\n\n.","journal-title":"Circulation"},{"issue":"3","key":"537_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2459\/01.jcm.0000260841.30415.62","volume":"8","author":"L Cal\u00f2","year":"2007","unstructured":"Cal\u00f2 L, De Ruvo E, Sette A, Sciarra L, Scioli R, Sebastiani F, et al. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown). 2007;8(3):138\u201343. doi:\n10.2459\/01.jcm.0000260841.30415.62\n\n.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"537_CR49","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1016\/j.ijcard.2013.07.017","volume":"168","author":"N Calvo","year":"2013","unstructured":"Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Int J Cardiol. 2013;168(4):4093\u20137. doi:\n10.1016\/j.ijcard.2013.07.017\n\n.","journal-title":"Int J Cardiol"},{"key":"537_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0002-9149(99)80799-1","volume":"76","author":"SG Chun","year":"1995","unstructured":"Chun SG, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76:47\u201350.","journal-title":"Am J Cardiol"},{"key":"537_CR51","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/nejmoa1408288","volume":"372","author":"A Verma","year":"2015","unstructured":"Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812\u201322. doi:\n10.1056\/nejmoa1408288\n\n.","journal-title":"N Engl J Med"},{"issue":"9994","key":"537_CR52","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0140-6736(15)60026-5","volume":"386","author":"L Macle","year":"2015","unstructured":"Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S, et al. Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet. 2015;386(9994):672\u20139. doi:\n10.1016\/S0140-6736(15)60026-5\n\n.","journal-title":"Lancet"},{"key":"537_CR53","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jacc.2009.02.022","volume":"53","author":"R Cappato","year":"2009","unstructured":"Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2009;53:1798\u2013803. doi:\n10.1016\/j.jacc.2009.02.022\n\n.","journal-title":"J Am Coll Cardiol"},{"key":"537_CR54","unstructured":"Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST). \nClinicaltrials.gov\n\n NCT01288352"},{"key":"537_CR55","unstructured":"Early Aggressive Invasive Intervention for Atrial Fibrillation (EARLY-AF). \nClinicaltrials.gov\n\n NCT02825979"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-017-0537-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-017-0537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-017-0537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T04:01:55Z","timestamp":1493956915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-017-0537-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1007\/s11936-017-0537-3","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]},"article-number":"38"}}